Carbohydrate antigen 125 (CA125) as a prognostic marker in the elderly with acute heart failure and preserved ejection fraction.

Background: Carbohydrate antigen 125 (CA125) has emerged as a new biomarker in heart failure. The objective of the study is to determine whether serum CA125 levels predict total mortality and readmissions at one year in patients >70 years old with acute heart failure (AHF) and preserved ejection fraction (PEF).

Methods: Multicenter prospective observational study, which included 359 patients (mean age 81.

Hyponatremia as predictor of worse outcome in real world patients admitted with acute heart failure.

Background: Our aim was to determine if hyponatremia, defined as serum sodium level < 135 mmol/L, is a predictor of worse outcome in a cohort of real-world patients with heartfailure (HF).

Methods: We used data of the National registry of HF (RICA) from Spain, an ongoing multicenter, prospective cohort study. The patients were assigned to two groups regarding sodium levels.

[Chronic obstructive pulmonary disease on inpatients with heart failure. GESAIC study results].

Background And Objective: The clinical relevance of Heart failure (HF) and chronic obstructive pulmonary disease (COPD) in the same patient is not well established. We decided to study the prevalence of COPD in patients admitted due to HF, to define their clinical profile and the relationship with adrenergic beta-blockers (BB) treatment.

Patients And Method: Prospective cohort of inpatients with HF admitted in 15 Internal Medicine Services from October 2005 to March 2006.

Ten-year experience with acenocoumarol treatment in an ambulatory cohort of Spanish patients.

Objective: To analyse incidence of hemorrhagic and thrombotic events in a series of ambulatory patients receiving acenocoumarol in a rural area of Spain (1997-2007).

Results: Out of 1,544 patients, 1,086 are receiving acenocoumarol at present (2% of our region's population). The total follow-up was 5,462 patients-years.

[Organizing pneumonia associated with the use of pegylated interferon alfa].

Organizing pneumonia is a well-differentiated clinical and histologic entity whose onset is usually subacute with respiratory symptoms and pulmonary infiltrates. Its origin may be unknown (cryptogenic) or it may be associated with various medical conditions, infectious diseases, or drugs. Diagnosis is confirmed by the presence of foci of organizing pneumonia in lung biopsy specimens.